SOURCE: Radient Pharmaceuticals Corporation

Radient Pharmaceuticals Corporation

November 16, 2010 08:45 ET

Radient Pharmaceuticals Files Extension for Third Quarter FY2010 Financial Results

TUSTIN, CA--(Marketwire - November 16, 2010) - Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today it has filed a Notification of Late Filing under Rule 12b‐25 of the Securities Exchange Act of 1934, as amended, with the Securities and Exchange Commission (the "SEC") for its Quarterly Report on Form 10-Q for the third quarter ended September 30, 2010. This filing provides an extension of time until November 22, 2010 to file the Company's Quarterly Report. 

The Form 10-Q for the quarter ended September 30, 2010 could not be filed within the prescribed period as additional time is necessary to analyze and compile information related to the Company's debt structure. The Company could not conduct this analysis or compile the necessary information within the prescribed period without incurring unreasonable effort or expense.

RPC Contact Information:
For additional information on Radient Pharmaceuticals, ADI and its portfolio of products visit the Company's corporate website at For Investor Relations information contact Kristine Szarkowitz at or 1.206.310.5323.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® Test Kits for colon-rectal cancer recurrence monitoring The company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease-state detection, treatment strategy and the monitoring of disease progression or recurrence. To learn more about our company, people and potentially life-saving cancer test, visit

Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Contact Information

  • RPC Contact:
    Kristine Szarkowitz
    Director-Investor Relations
    Email Contact
    (Tel) 206.310.5323